<DOC>
	<DOC>NCT01734811</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of a biological vaccine to prevent episodes of bronchospasm, induced by recurrent respiratory tract infections, in children, compared with a placebo group.</brief_summary>
	<brief_title>Efficacy and Safety Evaluation in Recurrent Bronchospasms</brief_title>
	<detailed_description>Double blind parallel placebo controlled study. The subjects will receive medication during 6 months and will be followed up during another six months.</detailed_description>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects whose parents /legal representative have given written informed consent. Both gender Subject up to 36 months of age. Subjects with recurrent bronchospasms ; 3 or more exacerbations in the last 12 months Subjects whose parents/legal representative have not given written informed consent. Subjects out of aged range Subjects with malignancies or chemotherapy treatment Subjects included in another clinical trial in the last 12 months. Subject in immunosuppressive or immunostimulatory treatment Subjects who have received iv gamma globulin in the past 12 months. Subjects diagnosed with candidiasis or fungal recurrent infections. Subjects diagnosed with malabsorption syndrome Subjects with clinical allergy to common aeroallergens in the geographical area. Subjects with hepatitis virus infections, HIV and tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Bronchospasm</keyword>
</DOC>